natgillin/translations-raw huggingface dataset:
In individuals who have ingested overdoses of loperamide HCl, cardiac events such as QT interval prolongation, torsades de pointes, other serious ventricular arrhythmias, cardiac arrest and syncope have been observed (see section 4.4).
Kod pojedinaca koji su se predozirali loperamidkloridom, opaženi su kardiološki događaji kao što je produženi QT interval, torsades de pointes, druge ozbiljne ventrikularne aritmije, srčani zastoj i sinkopa (vidjeti dio 4.4).
Talk to your doctor before using OPDIVO as it may cause: Solid organ transplant rejection
Obratite se svom liječniku prije nego primite OPDIVO jer on može uzrokovati: Odbacivanje presađenog solidnog organa (unutarnjeg organa čvrste građe)
3 - If you take more <brand name> than you should If you have taken too many <brand name>, immediately contact a doctor or hospital for advice.
Ako ste uzeli previše lijeka <naziv lijeka>, odmah se obratite liječniku za savjet ili otiđite u bolnicu.
Nivolumab monotherapy
Monoterapija nivolumabom
Cardiac events including QT prolongation and torsades de pointes have been reported in association with overdose.
Posebna upozorenja i mjere opreza pri uporabi Prijavljena je povezanost predoziranja i kardioloških događaja, uključujući produženi QT interval i torsades de pointes.
Nivolumab in combination with ipilimumab Frequency ‘not known': Solid organ transplant rejection
Učestalost „nepoznato”: Odbacivanje transplantiranog solidnog organa Nivolumab u kombinaciji s ipilimumabom2 - Što morate znati prije nego počnete primati OPDIVO
Your doctor may need to change your dose and/or to take other precautions:
Liječnik će Vam možda morati promijeniti dozu i/ili poduzeti druge mjere opreza:
Date of first authorisation: 19 January 2007 Date of latest renewal: 19 January 2012
Datum posljednje obnove: 19. siječnja 2012.
Irbesartan Hydrochlorothiazide Zentiva should be taken at least one hour before or four hours after these medications;
Irbesartan Hydrochlorothiazide Zentiva se mora uzeti najmanje jedan sat prije ili 4 sata poslije tih lijekova;
It is important that you continue to take Irbesartan Hydrochlorothiazide Zentiva until your doctor tells you otherwise.
Važno je da kontinuirano uzimate Irbesartan Hydrochlorothiazide Zentiva sve dok Vam liječnik ne odredi drugačije.
Irbesartan Hydrochlorothiazide Zentiva should not be given to children and adolescents (under 18 years).
Irbesartan Hydrochlorothiazide Zentiva se ne smije davati djeci i adolescentima (mlađima od 18 godina).
Other medicines and Irbesartan Hydrochlorothiazide Zentiva Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Drugi lijekovi i Irbesartan Hydrochlorothiazide Zentiva Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove.
When necessary, Irbesartan Hydrochlorothiazide Zentiva may be administered with another antihypertensive medicinal product (see sections 4.3, 4.4, 4.5 and 5.1).
Kada je potrebno, Irbesartan Hydrochlorothiazide Zentiva se može primjenjivati s drugim antihipertenzivnim lijekom (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
Since Irbesartan Hydrochlorothiazide Zentiva contains hydrochlorothiazide, it is not recommended during the first trimester of pregnancy.
Budući da Irbesartan Hydrochlorothiazide Zentiva sadrži hidroklorotiazid, ne preporučuje se tijekom prvog tromjesečja trudnoće.
Your doctor will normally advise you to stop taking Irbesartan Hydrochlorothiazide Zentiva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Irbesartan Hydrochlorothiazide Zentiva.
Vaš će Vam liječnik obično preporučiti da prestanete koristiti Irbesartan Hydrochlorothiazide Zentiva prije nego što zatrudnite ili čim saznate da ste trudni te će Vam savjetovati da uzmete neki drugi lijek umjesto lijeka Irbesartan Hydrochlorothiazide Zentiva.
If you forget to take Irbesartan Hydrochlorothiazide Zentiva If you accidentally miss a daily dose, just take the next dose as normal.
Ako ste zaboravili uzeti Irbesartan Hydrochlorothiazide Zentiva Ako slučajno zaboravite uzeti dnevnu dozu, samo uzmite sljedeću dozu kao što to obično i činite.
Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji ili blisteru iza oznake „EXP“.
If you get any of the above symptoms or get short of breath, stop taking Irbesartan Hydrochlorothiazide Zentiva and contact your doctor immediately.
Ako dobijete neki od tih simptoma ili ako imate nedostatak zraka, prestanite uzimati Irbesartan Hydrochlorothiazide Zentiva i odmah se obratite svome liječniku.
See also information under the heading “Do not take Irbesartan Hydrochlorothiazide Zentiva”.
Vidjeti također informacije pod naslovom „Nemojte uzimati Irbesartan Hydrochlorothiazide Zentiva“.
If Irbesartan Hydrochlorothiazide Zentiva is used during breast feeding, doses should be kept as low as possible.
Ako se Irbesartan Hydrochlorothiazide Zentiva primjenjuje tijekom dojenja, njegove doze trebaju biti što je moguće niže.
While this is not documented with Irbesartan Hydrochlorothiazide Zentiva, a similar effect should be anticipated.
Iako to nije dokumentirano za Irbesartan Hydrochlorothiazide Zentiva, može se očekivati sličan učinak.
In addition to the side effects listed above, chest pain, severe allergic reactions (anaphylactic shock) and decrease in te number of platelets (a blood cell essential for the clotting of the blood) have also been reported.
Uz gore navedene nuspojave zabilježene su i bol u prsnom košu, teške alergijske reakcije (anafilaktički šok) i smanjenje broja krvnih pločica (krvna stanica nužna za zgrušavanje krvi).
Irbesartan Hydrochlorothiazide Zentiva is not recommended for use in children and adolescents because the safety and efficacy have not been established.
Ne preporučuje se primjena lijeka Irbesartan Hydrochlorothiazide Zentiva u djece i adolescenata jer sigurnost i djelotvornost nisu utvrđene.
What Irbesartan Hydrochlorothiazide Zentiva is and what it is used for What you need to know before you take Irbesartan Hydrochlorothiazide Zentiva How to take Irbesartan Hydrochlorothiazide Zentiva Possible side effects
Što je Irbesartan Hydrochlorothiazide Zentiva i za što se koristi Što morate znati prije nego počnete uzimati Irbesartan Hydrochlorothiazide Zentiva Kako uzimati Irbesartan Hydrochlorothiazide Zentiva Moguće nuspojave
Irbesartan Hydrochlorothiazide Zentiva is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Irbesartan Hydrochlorothiazide Zentiva se ne preporučuje majkama koje doje, a Vaš liječnik može izabrati drugu terapiju ako želite dojiti, osobito ako se radi o dojenju novorođenčeta ili nedonoščeta.
Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels causing them to tighten.
Angiotenzin II je tvar koju stvara tijelo i koja se veže na receptore u krvnim žilama te uzrokuje njihovo sužavanje.
Hypotension - Volume-depleted patients: Irbesartan Hydrochlorothiazide Zentiva has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension.
Hipotenzija - bolesnici s hipovolemijom: Irbesartan Hydrochlorothiazide Zentiva je rijetko povezan sa simptomatskom hipotenzijom u hipertenzivnih bolesnika koji nemaju druge rizične faktore koji bi uzrokovali hipotenziju.
Irbesartan Hydrochlorothiazide Zentiva is used to treat high blood pressure, when treatment with irbesartan or hydrochlorothiazide alone did not provide adequate control of your blood pressure.
Irbesartan Hydrochlorothiazide Zentiva se primjenjuje za liječenje visokog krvnog tlaka kad liječenje samo irbesartanom ili samo hidroklorotiazidom ne osigurava odgovarajuću kontrolu krvnog tlaka.
As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy.
Kao što je to slučaj i s drugim lijekovima koji utječu na sustav reninangiotenzin, osobe crne rase koje boluju od hipertenzije imaju znatno slabiji odgovor na monoterapiju irbesartanom.
Efficacy and safety of Irbesartan Hydrochlorothiazide Zentiva as initial therapy for severe hypertension (defined as SeDBP ≥ 110 mmHg) was evaluated in a multicentre, randomized, doubleblind, active-controlled, 8-week, parallel-arm study.
Djelotvornost i sigurnost lijeka Irbesartan Hydrochlorothiazide Zentiva kao inicijalne terapije za tešku hipertenziju (dijastolički tlak u sjedećem položaju ≥ 110 mmHg) ocijenjena je u multicentričnom, randomiziranom, dvostruko-slijepom ispitivanju s aktivnom kontrolom, u trajanju od 8 tjedana, s paralelnom skupinom.
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):
Sljedeće promjene, zabilježene kod štakora i makaki majmuna koji su dobivali kombinaciju irbesartana/hidroklorotiazida u dozama od 10/10 i 90/90 mg/kg/dan, također su uočene i kod pojedinačne primjene ovih lijekova i/ili su bile sekundarne sniženju krvnog tlaka (nisu zabilježene značajne toksikološke interakcije):
Sanofi Winthrop Industrie 30-36, avenue Gustave Eiffel BP7166 F-37071, 37100 Tours France
Sanofi Winthrop Industrie 30-36, avenue Gustave Eiffel, BP 7466 F-37071, 37100 Tours Francuska
Because no information is available regarding the use of Irbesartan Hydrochlorothiazide Zentiva during breast-feeding, Irbesartan Hydrochlorothiazide Zentiva is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Budući da nema dostupnih podataka o upotrebi lijeka Irbesartan Hydrochlorothiazide Zentiva tijekom dojenja, ne preporučuje se njegova primjena tijekom dojenja i prednost treba dati drugoj terapiji s bolje ustanovljenim profilom sigurnosti primjene, osobito kada se doji novorođenče ili nedonošče.
Your doctor will instruct you how to switch from the previous treatment to Irbesartan Hydrochlorothiazide Zentiva.
Liječnik će Vas uputiti kako prijeći s prethodnog liječenja na Irbesartan Hydrochlorothiazide Zentiva.
Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in Irbesartan Hydrochlorothiazide Zentiva, minimal or no effects were reported.
Povišenje razine kolesterola i triglicerida bilo je povezano s terapijom tiazidima; međutim, pri dozi od 12,5 mg koliko sadrži Irbesartan Hydrochlorothiazide Zentiva, zabilježeni su minimalni učinci ili ih uopće nije bilo.
Children should not take Irbesartan Hydrochlorothiazide Zentiva Irbesartan Hydrochlorothiazide Zentiva should not be given to children under 18 years of age.
Djeca ne smiju uzimati Irbesartan Hydrochlorothiazide Zentiva Irbesartan Hydrochlorothiazide Zentiva ne smiju uzimati djeca mlađa od 18 godina.
Diuretic agents such as the hydrochlorothiazide contained in Irbesartan Hydrochlorothiazide Zentiva may have an effect on other medicines.
Diuretičke tvari, kao što je hidroklorotiazid iz lijeka Irbesartan Hydrochlorothiazide Zentiva, mogu imati učinke na druge lijekove.
Marketing Authorisation Holder Zentiva k.s.
Nositelj odobrenja za stavljanje lijeka u promet Zentiva k.s.
Irbesartan Hydrochlorothiazide Zentiva with food and drink Irbesartan Hydrochlorothiazide Zentiva can be taken with or without food.
Irbesartan Hydrochlorothiazide Zentiva s hranom i pićem Irbesartan Hydrochlorothiazide Zentiva se može uzeti s hranom ili bez nje.
Irbesartan Hydrochlorothiazide Zentiva can be taken once daily, with or without food.
Irbesartan Hydrochlorothiazide Zentiva se može uzimati jedanput na dan, s hranom ili bez nje.
Such conditions should be corrected before initiating therapy with Irbesartan Hydrochlorothiazide Zentiva.
Takva stanja treba korigirati prije započinjanja terapije lijekom Irbesartan Hydrochlorothiazide Zentiva.
Due to the hydrochlorothiazide contained in Irbesartan Hydrochlorothiazide Zentiva, if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, specially when getting up from a sitting position.
Ako pijete alkohol za vrijeme terapije ovim lijekom, zbog hidroklorotiazida u lijeku Irbesartan Hydrochlorothiazide Zentiva možete imati pojačan osjećaj omaglice prilikom ustajanja, posebno kod ustajanja iz sjedećeg položaja.
Tables 2 and 3 below detail the adverse reactions reported with the individual components of Irbesartan Hydrochlorothiazide Zentiva.
Tablice 2. i 3. prikazuju nuspojave prijavljene za pojedinačne komponente lijeka Irbesartan Hydrochlorothiazide Zentiva.
What you need to know before you take Irbesartan Hydrochlorothiazide Zentiva
Što morate znati prije nego počnete uzimati Irbesartan Hydrochlorothiazide Zentiva
Irbesartan Hydrochlorothiazide Zentiva is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Irbesartan Hydrochlorothiazide Zentiva se ne preporučuje uzimati u ranoj trudnoći te se ne smije uzimati nakon trećeg mjeseca trudnoće jer može ozbiljno naškoditi Vašem djetetu uzimate li ga nakon trećeg mjeseca trudnoće.
How to store Irbesartan Hydrochlorothiazide Zentiva Contents of the pack and other information
Kako čuvati Irbesartan Hydrochlorothiazide Zentiva Sadržaj pakiranja i druge informacije
Irbesartan Hydrochlorothiazide Zentiva is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Irbesartan Hydrochlorothiazide Zentiva se ne preporučuje uzimati u ranoj trudnoći, a ne smije se uzimati nakon trećeg mjeseca trudnoće jer može ozbiljno naškoditi Vašem djetetu primjenjujete li ga u tom razdoblju (vidjeti dio o trudnoći).
What Irbesartan Hydrochlorothiazide Zentiva is and what it is used for
Što je Irbesartan Hydrochlorothiazide Zentiva i za što se koristi
Although not specifically studied with the Irbesartan Hydrochlorothiazide Zentiva, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide.
Iako nisu provedena posebna ispitivanja s lijekom Irbesartan Hydrochlorothiazide Zentiva, ni s irbesartanom niti s hidroklorotiazidom nije primijećen povratak hipertenzije (tzv. rebound hipertenzija).
The two active ingredients in Irbesartan Hydrochlorothiazide Zentiva work together to lower blood pressure further than if either was given alone.
Dvije djelatne tvari lijeka Irbesartan Hydrochlorothiazide Zentiva zajedno snažnije djeluju na sniženje krvnog tlaka nego kad se daju pojedinačno.
Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskirenis therefore not recommended ( see sections 4.5 and 5.1).
Dvostruka blokada RAAS-a kombiniranom primjenom ACE inhibitora, blokatora angiotenzin II receptora ili aliskirena stoga se ne preporučuje (vidjeti dijelove 4.5 i 5.1).
You should discontinue Irbesartan Hydrochlorothiazide Zentiva treatment and seek medical attention.
Prestanite uzimati Irbesartan Hydrochlorothiazide Zentiva i zatražite liječničku pomoć.
Conversely, due to the irbesartan component of Irbesartan Hydrochlorothiazide Zentiva hyperkalaemia might occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus.
Nasuprot tomu, zbog irbesartana u sastavu lijeka Irbesartan Hydrochlorothiazide Zentiva može se pojaviti hiperkalijemija, posebice ako istodobno postoji narušena funkcija bubrega i/ili srčano zatajenje i šećerna bolest.
Other antihypertensive agents: the antihypertensive effect of Irbesartan Hydrochlorothiazide Zentiva may be increased with the concomitant use of other antihypertensive agents.
Ostali antihipertenzivni lijekovi: antihipertenzivni učinak lijeka Irbesartan Hydrochlorothiazide Zentiva može se pojačati istodobnim uzimanjem drugih antihipertenziva.
Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously with non-steroidal anti- inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (>3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Nesteroidni protuupalni lijekovi: kad se antagonisti angiotenzina II primjenjuju istodobno s nesteroidnim protuupalnim lijekovima (npr. selektivnim inhibitorima COX-2, acetilsalicilatnom kiselinom (> 3 g/dan) i neselektivnim nesteroidnim protuupalnim lijekovima), može doći do slabljenja antihipertenzivnog učinka.
There is no difference in response to Irbesartan Hydrochlorothiazide Zentiva, regardless of age or gender.
Ne postoji razlika u terapijskom odgovoru bolesnika na Irbesartan Hydrochlorothiazide Zentiva s obzirom na dob ili spol.
Irbesartan Hydrochlorothiazide Zentiva is unlikely to affect your ability to drive or use machines.
Irbesartan Hydrochlorothiazide Zentiva ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima i strojevima.
No specific information is available on the treatment of overdose with Irbesartan Hydrochlorothiazide Zentiva.
Nema dostupnih specifičnih podataka o liječenju predoziranja lijekom Irbesartan Hydrochlorothiazide Zentiva.
Protect your skin from sun exposure and UV rays while taking Karvezide.
Zaštitite svoju kožu od izlaganja suncu i UV zrakama za vrijeme uzimanja lijeka Irbesartan Hydrochlorothiazide Zentiva
The recommended dose of Irbesartan Hydrochlorothiazide Zentiva is one or two tablets a day.
Uobičajena doza lijeka Irbesartan Hydrochlorothiazide Zentiva je jedna ili dvije tablete na dan.
Please see section 2 “Irbesartan Hydrochlorothiazide Zentiva contains lactose”.
Vidjeti dio 2., „Irbesartan Hydrochlorothiazide Zentiva sadrži laktozu“.
No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is ≥30 ml/min (see sections 4.3 and 4.4).
Nije potrebna prilagodba doze u bolesnika s oštećenom funkcijom bubrega čiji je klirens kreatinina ≥ 30 ml/min (vidjeti dijelove 4.3 i 4.4).
Side effects reported in clinical studies for patients treated with Irbesartan Hydrochlorothiazide Zentiva were:
Nuspojave prijavljene u kliničkih ispitivanjima kod bolesnika liječenih lijekom Irbesartan Hydrochlorothiazide Zentiva:
Due to the hydrochlorothiazide component, Irbesartan Hydrochlorothiazide Zentiva is not recommended for patients with severe renal dysfunction (creatinine clearance <30 ml/min).
Zbog hidroklorotiazida u sastavu lijeka, Irbesartan Hydrochlorothiazide Zentiva se ne preporučuje bolesnicima s teško oštećenom funkcijom bubrega (klirens kreatinina < 30 ml/min.).
Food does not affect the bioavailability of Irbesartan Hydrochlorothiazide Zentiva.
Hrana ne utječe na bioraspoloživost lijeka Irbesartan Hydrochlorothiazide Zentiva.
Therefore, the combination of lithium and Irbesartan Hydrochlorothiazide Zentiva is not recommended (see section 4.4).
Stoga se kombinacija litija i lijeka Irbesartan Hydrochlorothiazide Zentiva ne preporučuje (vidjeti dio 4.4).
Preparations containing lithium should not be taken with Irbesartan Hydrochlorothiazide Zentiva without close supervision by your doctor.
Pripravci koji sadrže litij ne smiju se uzimati s lijekom Irbesartan Hydrochlorothiazide Zentiva bez pomnog liječničkog nadzora.
Renal impairment and kidney transplantation: when Irbesartan Hydrochlorothiazide Zentiva is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Oštećena funkcija bubrega i transplantacija bubrega: kad Irbesartan Hydrochlorothiazide Zentiva uzimaju bolesnici s oštećenom funkcijom bubrega, preporučuje se periodički kontrolirati razine kalija, kreatinina i mokraćne kiseline u serumu.
Following oral administration of Irbesartan Hydrochlorothiazide Zentiva, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Nakon peroralne primjene lijeka Irbesartan Hydrochlorothiazide Zentiva apsolutna oralna bioraspoloživost je 60-80% za irbesartan, odnosno 50-80% za hidroklorotiazid.
You should also tell your doctor: if you are on a low-salt diet if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in Irbesartan Hydrochlorothiazide Zentiva) if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal if you are going to have an operation (surgery) or be given anaesthetics if you have changes in your vision or pain in one or both of your eyes while taking Irbesartan Hydrochlorothiazide Zentiva.
Svog liječnika također trebate obavijestiti: ako ste na dijeti s malim unosom soli ako imate simptome kao što su neuobičajena žeđ, suha usta, opća slabost, omamljenost, grčevi ili bol u mišićima, mučnina, povraćanje ili neuobičajeno brzi otkucaji srca jer oni mogu upućivati na pretjerani učinak hidroklorotiazida (sastojak lijeka Irbesartan Hydrochlorothiazide Zentiva) ako iskusite povećanu osjetljivost kože na sunce s pojavom simptoma sunčanih opeklina (kao što su crvenilo kože, svrbež, oticanje, nastanak mjehurića), a pojavljuju se brže nego što je normalno ako trebate ići na operaciju (kirurški zahvat) ili trebate primiti anestetike ako tijekom uzimanja lijeka Irbesartan Hydrochlorothiazide Zentiva primijetite promjene vida ili bol u jednom ili oba oka.
The recommended dose of Irbesartan Hydrochlorothiazide Zentiva is one tablet a day.
Uobičajena doza lijeka Irbesartan Hydrochlorothiazide Zentiva je jedna tableta na dan.
Irbesartan Hydrochlorothiazide Zentiva is not indicated in patients with severe hepatic impairment.
Irbesartan Hydrochlorothiazide Zentiva nije indiciran u bolesnika s teško oštećenom funkcijom jetre.
Potassium-sparing diuretics, potassium supplements or potassiumcontaining salts substitutes should be co-administered cautiously with Irbesartan Hydrochlorothiazide Zentiva (see section 4.5).
Diuretici koji štede kalij, nadomjesci kalija ili nadomjesci soli koji sadrže kalij moraju se s oprezom istodobno primjenjivati s lijekom Irbesartan Hydrochlorothiazide Zentiva (vidjeti dio 4.5).
Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with Irbesartan Hydrochlorothiazide Zentiva.
Dodatne informacije o pojedinačnim komponentama lijeka: uz navedene nuspojave kombiniranog lijeka, moguće nuspojave lijeka Irbesartan Hydrochlorothiazide Zentiva mogu biti i one prethodno prijavljene za pojedinačne komponente lijeka.
Based on its pharmacodynamic properties, Irbesartan Hydrochlorothiazide Zentiva is unlikely to affect the ability to drive and use machines.
Na temelju farmakodinamičkih svojstava, Irbesartan Hydrochlorothiazide Zentiva ne bi trebao utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen.
Stanje dinamičke ravnoteže koncentracija u plazmi postiže se 3 dana nakon uvođenja doziranja jedanput na dan.
Common:
sustava: